ArticleThe Journal of allergy and clinical immunology2015
IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens.
Article in The Journal of allergy and clinical immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 1 synthesis or guideline pooled it, 261 citations in OpenAlex.
- Immune Tolerance vs. Immune Resistance: The Interaction Between Host and Pathogens in Infectious Diseases.Frontiers in veterinary science · 2022Pooled it
- High- and Low-Dose Oral Sesame Immunotherapy: Interim Analysis of a Randomized Single-Center Open-Label Trial.Journal of asthma and allergy · 2026Trial
- Baseline basophil activation and early suppression is associated with clinical outcome after peanut sublingual immunotherapy.The Journal of allergy and clinical immunology · 2025Trial
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.Allergy · 2025Trial
- Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.Allergy · 2025Trial
- Progenitor cell-derived basophils: A novel barcoded passive degranulation assay in allergic diseases.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2023Trial
- Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy.The journal of allergy and clinical immunology. In practice · 2022Trial
- Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy.The Journal of allergy and clinical immunology · 2022Trial
- HLA alleles and sustained peanut consumption promote IgG4 responses in subjects protected from peanut allergy.The Journal of clinical investigation · 2022Trial
- High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy.Cell reports. Medicine · 2021Trial
- Evolution of epitope-specific IgE and IgGThe Journal of allergy and clinical immunology · 2021Trial
- Peanut diversity and specific activity are the dominant IgE characteristics for effector cell activation in children.The Journal of allergy and clinical immunology · 2021Trial
- Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.The Journal of allergy and clinical immunology · 2020Trial
- Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.The Journal of allergy and clinical immunology · 2019Trial
- Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.Lancet (London, England) · 2019Trial
- Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2019Trial
- Ratios of specific IgGClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019Trial
- Trial
- Single B-cell deconvolution of peanut-specific antibody responses in allergic patients.The Journal of allergy and clinical immunology · 2016Trial
- Randomized trial of peanut consumption in infants at risk for peanut allergy.The New England journal of medicine · 2015Trial
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
Abstract
backgroundMost children with detectable peanut-specific IgE (P-sIgE) are not allergic to peanut. We addressed 2 non-mutually exclusive hypotheses for the discrepancy between allergy and sensitization: (1) differences in P-sIgE levels between children with peanut allergy (PA) and peanut-sensitized but tolerant (PS) children and (2) the presence of an IgE inhibitor, such as peanut-specific IgG4 (P-sIgG4), in PS patients.
methodsTwo hundred twenty-eight children (108 patients with PA, 77 PS patients, and 43 nonsensitized nonallergic subjects) were studied. Levels of specific IgE and IgG4 to peanut and its components were determined. IgE-stripped basophils or a mast cell line were used in passive sensitization activation and inhibition assays. Plasma of PS subjects and patients submitted to peanut oral immunotherapy (POIT) were depleted of IgG4 and retested in inhibition assays.
resultsBasophils and mast cells sensitized with plasma from patients with PA but not PS patients showed dose-dependent activation in response to peanut. Levels of sIgE to peanut and its components could only partially explain differences in clinical reactivity between patients with PA and PS patients. P-sIgG4 levels (P = .023) and P-sIgG4/P-sIgE (P < .001), Ara h 1-sIgG4/Ara h 1-sIgE (P = .050), Ara h 2-sIgG4/Ara h 2-sIgE (P = .004), and Ara h 3-sIgG4/Ara h 3-sIgE (P = .016) ratios were greater in PS children compared with those in children with PA. Peanut-induced activation was inhibited in the presence of plasma from PS children with detectable P-sIgG4 levels and POIT but not from nonsensitized nonallergic children. Depletion of IgG4 from plasma of children with PS (and POIT) sensitized to Ara h 1 to Ara h 3 partially restored peanut-induced mast cell activation (P = .007).
conclusionsDifferences in sIgE levels and allergen specificity could not justify the clinical phenotype in all children with PA and PS children. Blocking IgG4 antibodies provide an additional explanation for the absence of clinical reactivity in PS patients sensitized to major peanut allergens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.